January 20, 2026Eyebright Medical（Beijing）Eyebright Medical Technology (Beijing) Co., Ltd. Collaborates with Delta Medical（Chongqing）Delta Medical and its founder Jianbo Li sign《Letter of Intent for Investment》，Plan to acquire no less than 51% of Delta Medical's equity through M&A loans and自有资金.，In order to gain control。This transaction aims to expand the company's layout in the field of sports medicine.，Cultivate New Profit Growth Points。
In core decision-making aspects，Eyebright Medical plans to implement its“Endogenous Growth and Exogenous Development”The dual-drive strategy，Extend the business to the high-potential sports medicine track。After the transaction is completed，Eyebright Medical to Become the Controlling Shareholder of Delta Medical。
Delta Medical is a professional manufacturer that designs and produces surgical instruments for sports medicine, intraoperative consumables, and rehabilitation products. It is committed to the research, development, and production of arthroscopic surgery and sports rehabilitation products. The company owns a full set of machining and surface treatment production lines under a joint venture brand, as well as a Class 10,000 cleanroom packaging workshop that meets the production requirements for Class III implants. It also has a complete set of high-precision testing equipment, including projectors, hardness testers, tensile testers, roughness testers, and sterile environment controls.
Key Data Shows，Delta Medical's overall valuation is estimated to be no more than 1 billion yuan.。The company, as a national high-tech enterprise and“Specialized, Refined, Unique, and Innovative”Little Giant Enterprise，Holding 276 patents，Has Obtained 34 Class III Medical Device Registration Certificates。Financial Aspect，Its unaudited operating revenue for the year 2025 is RMB 286.1325 million.，Adjusted net profit was RMB 23.6023 million。The transaction set performance-based wagering clauses.，Delta Medical commits to achieving a total audited net profit of no less than 165 million yuan from 2026 to 2028.，If the goal is not achieved，Founder Needs to Compensate Eyebright Medical with Equity；If exceeding the target，Management Team to Receive Cash Bonus。
Timeline，Signed this time《Letter of Intent for Investment》Set a 6-month exclusivity period。The transaction is still subject to the completion of due diligence.、Negotiate and finalize the transaction terms、Sign a formal agreement and fulfill the necessary internal review procedures of the company.。
In terms of impact scope，This transaction does not constitute a related party transaction or a major asset restructuring.。If successfully implemented，Eyebright Medical to integrate Delta Medical in sports medicine implants、Surgical Instruments、Research and development in the fields of arthroscopic equipment and rehabilitation devices、Production and Sales Resources。Delta Medical Has Been Selected for the National High-Value Medical Consumables Group A Procurement，Sales network covers China and multiple overseas regions.，Expected to generate business synergy with Eyebright Medical，Jointly Promote the Localization Process in the Field of Sports Medicine。Currently，This letter of intent is confidential except as otherwise provided herein.、Except for exclusive and a few other clauses，Most of the content is not legally binding.，There is uncertainty about whether the final deal can be reached.
Eyebright Medical Technology (Beijing) Co., Ltd., a STAR Market listed company (Stock abbreviation: Eyebright Medical, Stock code: 688050), is located in the Changping Park of the Zhongguancun National Independent Innovation Demonstration Zone in Beijing. It is a national high-tech enterprise and a national-level specialized, refined, distinctive, and innovative "little giant" enterprise.
The company is an innovation-driven ophthalmic medical device manufacturer, with products covering three major fields: ophthalmic surgical treatment, myopia prevention and control, and vision care. It is committed to providing one-stop solutions for ophthalmic surgery, refractive error correction, and optical consumer needs. Based on three core products—artificial crystalline lenses, orthokeratology lenses, and contact lenses—the company has strategically expanded its coverage of a full life-cycle product pipeline for eye health.
If there are any inaccuracies or infringement issues above, please feel free to contact the author for removal. Thank you!
